

CONTENTS

Corporate Information	2
Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income	4
Condensed Consolidated Statement of Financial Position	6
Condensed Consolidated Statement of Changes in Equity	8
Condensed Consolidated Statement of Cash Flows	10
Notes to the Condensed Consolidated Interim Financial Statements	11
Management Discussion and Analysis	21
Other Information	27

CORPORATE INFORMATION

BOARD OF DIRECTORS

The Board of Directors as now constituted is listed below:

Executive Director

Mr. Wang Jia Jun (*Chief Executive Officer*)

Non-Executive Director

Dr. Xiao Zhixin

Independent Non-Executive Directors

Mr. Wong Hon Kit

Dr. Liu Yongping

Mr. Ho Man

AUTHORISED REPRESENTATIVES

Mr. Wang Jia Jun

Mr. Tam Sze Kin

COMPANY SECRETARY

Mr. Tam Sze Kin

AUDIT COMMITTEE

Mr. Wong Hon Kit (*Chairman*)

Dr. Liu Yongping

Mr. Ho Man

REMUNERATION COMMITTEE

Mr. Wong Hon Kit (*Chairman*)

Dr. Liu Yongping

Mr. Ho Man

Mr. Wang Jia Jun

NOMINATION AND CORPORATE GOVERNANCE COMMITTEE

Mr. Wang Jia Jun (*Chairman*)

Mr. Wong Hon Kit

Dr. Liu Yongping

Mr. Ho Man

REGISTERED OFFICE

Third Floor

Century Yard, Cricket Square

P.O. Box 902

Grand Cayman

KY1-1103

Cayman Islands

HEAD OFFICE AND PRINCIPAL PLACE OF BUSINESS IN HONG KONG

Suite 1801, 18/F., Tower 1
The Gateway, Harbour City
25 Canton Road, Kowloon
Hong Kong

PRINCIPAL SHARE REGISTRAR AND TRANSFER OFFICE

Tricor Services (Cayman Islands) Limited
Third Floor
Century Yard, Cricket Square
P.O. Box 902
Grand Cayman
KY1-1103
Cayman Islands

HONG KONG BRANCH SHARE REGISTRAR AND TRANSFER OFFICE

Tricor Investor Services Limited
17/F, Far East Finance Centre
16 Harcourt Road
Hong Kong

PRINCIPAL BANKERS

Agricultural Bank of China Limited
Yangchun Dongmen sub-branch, PRC
China Construction Bank Corporation
Meizhou Wuhua Station branch, PRC
Industrial and Commercial Bank of
China Limited
Wuchuan City sub-branch, PRC
Bank of Communications Co., Limited
Hong Kong Branch

AUDITORS

HLB Hodgson Impey Cheng Limited
Certified Public Accountants
31/F, Gloucester Tower
The Landmark
11 Pedder Street
Central, Hong Kong

STOCK CODE

401

WEBSITE

www.wanjia-gp.com

FINANCIAL HIGHLIGHTS

- Revenue for the Period was approximately HK\$93.373 million (2022: approximately HK\$90.146 million), representing an increase of approximately 3.58% as compared with the corresponding period in 2022. The increase was driven by the increase in revenue from the Hemodialysis Business.
- Loss for the Period from operations attributable to owners of the Company was approximately HK\$3.050 million (2022: approximately HK\$2.506 million).
- The Group had total cash and cash equivalents of approximately HK\$15.765 million as at 30 September 2023 (31 March 2023: approximately HK\$9.876 million).
- The basic and diluted loss per share was approximately HK\$0.54 cents (2022: approximately HK\$0.45 cents).
- The Board does not recommend the payment of an interim dividend (2022: Nil).

INTERIM RESULTS

The board of directors (the “**Board**”, and the members of the Board, the “**Directors**”) of Wanjia Group Holdings Limited (the “**Company**”) is pleased to present the unaudited condensed consolidated interim results of the Company and its subsidiaries (collectively, the “**Group**”) for the six months ended 30 September 2023 (the “**Period**”), with the unaudited comparative figures for the corresponding period in 2022 as follows:

Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income

		Six months ended 30 September	
		2023	2022
	Notes	HK\$'000	HK\$'000
		(Unaudited)	(Unaudited)
Revenue	4 & 5	93,373	90,146
Cost of sales		<u>(66,704)</u>	<u>(63,408)</u>
Gross profit		26,669	26,738
Other revenue and income		3,011	259
Selling and distribution expenses		(19,791)	(17,999)
Administrative expenses		<u>(11,883)</u>	<u>(10,150)</u>
Loss from operations	6	(1,994)	(1,152)
Finance costs	7	<u>(893)</u>	<u>(938)</u>
Loss before taxation		(2,887)	(2,090)
Taxation	8	<u>(146)</u>	<u>(396)</u>
Loss for the period		(3,033)	(2,486)
Other comprehensive expense for the period, net of tax			
<i>Item that may be reclassified subsequently to profit or loss:</i>			
Exchange differences on translating foreign operations		<u>(4,385)</u>	<u>(10,939)</u>
Total comprehensive expense for the period		<u>(7,418)</u>	<u>(13,425)</u>

Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income

	Notes	Six months ended 30 September	
		2023 HK\$'000 (Unaudited)	2022 HK\$'000 (Unaudited)
(Loss)/profit for the period attributable to:			
Owners of the Company		(3,050)	(2,506)
Non-controlling interests		<u>17</u>	<u>20</u>
		<u>(3,033)</u>	<u>(2,486)</u>
Total comprehensive (expense)/income for the period attributable to:			
Owners of the Company		(7,419)	(13,423)
Non-controlling interests		<u>1</u>	<u>(2)</u>
		<u>(7,418)</u>	<u>(13,425)</u>
Loss per share attributable to owners of the Company			
– Basic and diluted (<i>HK cents per share</i>)	9	<u>(0.54)</u>	<u>(0.45)</u>

Condensed Consolidated Statement of Financial Position

		At 30 September 2023 HK\$'000 (Unaudited)	At 31 March 2023 HK\$'000 (Audited)
	Notes		
Non-current assets			
Property, plant and equipment	10	28,190	31,679
Right-of-use asset		13,464	15,807
Goodwill		49,093	49,093
		<u>90,747</u>	<u>96,579</u>
Current assets			
Inventories		11,859	12,631
Trade and other receivables and deposits	11	56,901	50,659
Cash and cash equivalents		15,765	9,876
		<u>84,525</u>	<u>73,166</u>
Assets classified as held for sale		–	3,703
Total current assets		<u>84,525</u>	<u>76,869</u>
Total assets		<u><u>175,272</u></u>	<u><u>173,448</u></u>
Capital and reserves			
Share capital	12	28,011	28,011
Reserves		82,943	90,186
Equity attributable to owners of the Company		<u>110,954</u>	<u>118,197</u>
Non-controlling interests		<u>2,031</u>	<u>2,030</u>
Total equity		<u>112,985</u>	<u>120,227</u>

Condensed Consolidated Statement of Financial Position

		At 30 September 2023 HK\$'000 (Unaudited)	At 31 March 2023 HK\$'000 (Audited)
	Notes		
Current liabilities			
Trade and other payables	13	37,425	23,897
Lease liabilities		2,424	2,569
Amount due to a director	14	3,700	–
Borrowings	15	4,338	7,450
Tax payables		1,256	1,320
		<u>49,143</u>	<u>35,236</u>
Liabilities associated with assets classified as held for sales		–	2,838
		<u>49,143</u>	<u>38,074</u>
Non-current liabilities			
Lease liabilities		<u>13,144</u>	<u>15,147</u>
		<u>13,144</u>	<u>15,147</u>
Total equity and liabilities		<u><u>175,272</u></u>	<u><u>173,448</u></u>
Net current assets		<u><u>35,382</u></u>	<u><u>38,795</u></u>
Total assets less current liabilities		<u><u>126,129</u></u>	<u><u>135,374</u></u>

Condensed Consolidated Statement of Changes in Equity

	Attributable to owners of the Company										
	Share capital HK\$'000	Share premium HK\$'000	Other reserve HK\$'000 (Note (a))	Share option reserve HK\$'000 (Note (b))	Contribution reserve HK\$'000 (Note (c))	Translation reserve HK\$'000 (Note (d))	Statutory reserve HK\$'000 (Note (e))	Accumulated losses HK\$'000	Sub-total HK\$'000	Non-controlling interests HK\$'000	Total HK\$'000
At 1 April 2022 (audited)	28,011	60,299	(2,878)	5,636	866,811	12,219	20,821	(864,740)	126,179	1,917	128,096
(Loss)/profit for the period	-	-	-	-	-	-	-	(2,506)	(2,506)	20	(2,486)
Other comprehensive expense for the period	-	-	-	-	-	(10,917)	-	-	(10,917)	(22)	(10,939)
Total comprehensive expense for the period	-	-	-	-	-	(10,917)	-	(2,506)	(13,423)	(2)	(13,425)
Share-based payment	-	-	-	1	-	-	-	-	1	-	1
At 30 September 2022 (unaudited)	28,011	60,299	(2,878)	5,637	866,811	1,302	20,821	(867,246)	112,757	1,915	114,672
At 1 April 2023 (audited)	28,011	60,299	(2,878)	5,641	866,811	2,412	22,223	(864,322)	118,197	2,030	120,227
(Loss)/profit for the period	-	-	-	-	-	-	-	(3,050)	(3,050)	17	(3,033)
Other comprehensive expense for the period	-	-	-	-	-	(4,369)	-	-	(4,369)	(16)	(4,385)
Total comprehensive (expense)/income for the period	-	-	-	-	-	(4,369)	-	(3,050)	(7,419)	1	(7,418)
Share-based payment	-	-	-	176	-	-	-	-	176	-	176
At 30 September 2023 (unaudited)	28,011	60,299	(2,878)	5,817	866,811	(1,957)	22,223	(867,372)	110,954	2,031	112,985

Notes:

(a) Other reserve

The other reserve represented the difference between the Company's shares of nominal value of the paid-up capital of subsidiaries acquired over the Company's cost of acquisition of the subsidiaries under common control upon the reorganisation and deemed acquisition of a subsidiary's equity interest.

(b) Share option reserve

The reserve represents the fair value of the actual or estimated number of unexercised share options grants to eligible persons, including any full-time and part-time employee, director, consultant or advisor of the Company and its subsidiaries recognised in accordance with the share option scheme.

Condensed Consolidated Statement of Changes in Equity

(c) Contribution reserve

Capitalisation of the outstanding amount of approximately HK\$866,811,000 due from Timely Hero Enterprises Limited (“**Timely Hero**”) to Hua Xia Healthcare Holdings Limited (“**Hua Xia**”) on 3 September 2013 in consideration of (i) the allotment and issue 1 share of US\$1 in the share capital of Timely Hero to Luxuriant Expand Global Investment Limited (“**Luxuriant Expand**”), credited as fully paid up, at the direction of Hua Xia; and (ii) the allotment and issue of a total of 100 shares of US\$1 each in the share capital of Luxuriant Expand, all credited as fully paid up, to Hua Xia in consideration of its receipt of 1 share in Timely Hero at the direction of Hua Xia. Details of the reorganisation were set out in the paragraph headed “The Reorganisation” in the section headed “Corporate history, development and Reorganisation” in the prospectus dated 30 September 2013.

(d) Translation reserve

The translation reserve comprises all foreign exchange differences arising from the translation of the financial statements of foreign operations. The reserve is dealt with in accordance with the accounting policies set out in Note 3.

(e) Statutory reserve

As stipulated by the relevant laws and regulations of the PRC, the subsidiaries of the Company establishing in the PRC shall set aside 10% of its net profit after taxation for the statutory surplus reserve fund (except where the reserve balances has reached 50% of the subsidiaries’ paid up capital). The reserve fund can only be used, upon approval by the Board of Directors and by the relevant authority, to offset accumulated losses or increase capital.

(f) Distributable reserve

Pursuant to applicable statutory provisions of the Cayman Islands, the Company did not have reserve available for distribution to the shareholders of the Company for the Period.

The accompanying notes form an integral part of these consolidated financial statements.

Condensed Consolidated Statement of Cash Flows

	Six months ended 30 September	
	2023	2022
	HKS'000	HKS'000
	(Unaudited)	(Unaudited)
Net cash from operating activities	10,056	13,905
Net cash used in investing activities	(254)	(442)
Net cash from financing activities	1,384	4,079
Net increase in cash and cash equivalents	11,186	17,542
Cash and cash equivalents at 1 April	9,876	5,768
Effect of foreign currency exchange rate changes on cash and cash equivalents	(5,297)	(10,106)
Cash and cash equivalents at 30 September	15,765	13,204

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

1. General information

Wanjia Group Holdings Limited (the “**Company**”) was incorporated as an exempted Company with limited liabilities in the Cayman Islands. The Company’s immediate holding company and ultimate holding company is Power King Investment Development Limited, a company incorporated in British Virgin Islands (the “**BVI**”). The Company’s shares are listed on the Main Board of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The address of the registered office of the Company is Third Floor, Century Yard, Cricket Square, P.O. Box 902, Grand Cayman, KY1-1103, Cayman Islands. The head office and principal place of business of the Company in Hong Kong is located at Suite 1801, 18/F, Tower 1 The Gateway, Harbour City, 25 Canton Road, Kowloon, Hong Kong.

The Company is an investment holding Company and its subsidiaries (together with the Company, the “**Group**”) are principally engaged in pharmaceutical wholesale and distribution business, and hemodialysis treatment and consultancy service business in the People’s Republic of China (the “**PRC**”).

The unaudited condensed consolidated financial statements are presented in Hong Kong dollars (“**HK\$**”), which is the same as functional currency of the Company, and the functional currency of the most of the subsidiaries are Renminbi (“**RMB**”). The Board of Directors considered that it is more appropriate to present the unaudited condensed consolidated financial statements in HK\$ as the shares of the Company are listed on the Stock Exchange. All values are rounded to the nearest thousands (HK\$’000), unless otherwise stated.

2. Basis of preparation and principal accounting policies

The unaudited condensed consolidated interim financial statements for the six months ended 30 September 2023 (the “Interim Financial Statements”) have been prepared in accordance with Hong Kong Accounting Standard (“HKAS”) 34 “Interim Financial Reporting” issued by the Hong Kong Institute of Certified Public Accountants (“HKICPA”) as well as with the applicable disclosure requirements of Appendix 16 to the Rules Governing the Listing of Securities (the “Listing Rules”) of the Stock Exchange.

The Interim Financial Statements have been prepared on the historical cost basis except for certain financial instruments, which are measured at fair values, as appropriate.

Other than changes in accounting policies resulting from application of new and revised Hong Kong Financial Reporting Standards (“HKFRSs”), the accounting policies and methods of computation used in the Interim Financial Statements are the same as those followed in the preparation of the Group’s annual financial statements for the year ended 31 March 2023.

These unaudited condensed consolidated financial statements should be read in conjunction with the 2023 consolidated financial statements for the year ended 31 March 2023.

3. Significant Accounting Policies

In the current interim period, the Group has applied the following amendments to HKFRSs issued by the HKICPA, for the first time, which are mandatorily effective for the Group’s annual period beginning on 1 January 2023 for the preparation of the Group’s condensed consolidated financial statements:

HKFRS 17 (including the October 2020 and February 2022 Amendments to HKFRS 17)	Insurance Contracts
Amendments to HKAS 1 and HKFRS Practice Statement 2	Disclosure of Accounting Policies
Amendments to HKAS 8	Definition of Accounting Estimates
Amendments to HKAS 12	Deferred Tax related to Assets and Liabilities arising from a Single Transaction
Amendments to HKAS 12	International Tax Reform – Pillar Two Model Rules

The application of these new and amendments to HKFRSs has had no material impact on the Group’s financial position and financial performance for the current and/or prior periods and/or on the disclosures set out in the Interim Financial Statements.

The Group has not applied any new and amendments to HKFRSs that have been issued but not yet effective. The application of these new HKFRSs will not have material impact on the condensed consolidated financial statement of the Group.

4. Revenue

The principal activities of the Group are pharmaceutical wholesale and distribution business and provides hemodialysis treatment and consultancy service in the PRC and the revenue from contract with customers recognised at a point in time.

5. Segment information

Information reported internally to the chief operating decision maker for the purpose of resource allocation and assessment of segment performance focuses on types of goods or services delivered or provided. The Group organised into two operating divisions: (a) pharmaceutical wholesale and distribution business and (b) hemodialysis treatment and consultancy service business in the PRC. These divisions are the bases on which the Group reports its segment information.

Information regarding the Group's reportable segments is presented below.

	Pharmaceutical wholesale and distribution business HK\$'000	Hemodialysis treatment and consultancy service business HK\$'000	Consolidated HK\$'000
<i>Six months ended 30 September 2023 (Unaudited)</i>			
Revenue			
Revenue from external customers	<u>25,139</u>	<u>68,234</u>	<u>93,373</u>
Results			
Segment results	<u>126</u>	<u>2,473</u>	2,599
Unallocated corporate income and expenses, net			<u>(4,593)</u>
Loss from operations			(1,994)
Finance costs			<u>(893)</u>
Loss before taxation			(2,887)
Taxation			<u>(146)</u>
Loss for the period			<u><u>(3,033)</u></u>

	Pharmaceutical wholesale and distribution business HK\$'000	Hemodialysis treatment and consultancy service business HK\$'000	Consolidated HK\$'000
--	---	--	--------------------------

Six months ended 30 September 2022 (Unaudited)

Revenue

Revenue from external customers	27,560	62,586	90,146
---------------------------------	--------	--------	--------

Results

Segment results	280	2,089	2,369
-----------------	-----	-------	-------

Unallocated corporate income and expenses, net			(3,521)
---	--	--	---------

Loss from operations			(1,152)
----------------------	--	--	---------

Finance costs			(938)
---------------	--	--	-------

Loss before taxation			(2,090)
----------------------	--	--	---------

Taxation			(396)
----------	--	--	-------

Loss for the period			(2,486)
---------------------	--	--	---------

Note:

No inter-segment sales under pharmaceutical wholesale and distribution business and hemodialysis treatment and consultancy service business for the Period (2022: Nil). Inter-segment sales are charged at arm's length and fully eliminated under consolidation.

Segment assets and liabilities

	Pharmaceutical wholesale and distribution business HK\$'000	Hemodialysis treatment and consultancy service business HK\$'000	Consolidated HK\$'000
<i>As at 30 September 2023 (Unaudited)</i>			
Assets			
Segment assets	20,229	148,423	168,652
Unallocated corporate assets			6,620
Consolidated total assets			175,272
Liabilities			
Segment liabilities	7,139	46,766	53,905
Unallocated corporate liabilities			8,382
Consolidated total liabilities			62,287
<i>As at 31 March 2023 (Audited)</i>			
Assets			
Segment assets	21,050	147,998	169,048
Unallocated corporate assets			4,400
Consolidated total assets			173,448
Liabilities			
Segment liabilities	7,309	41,196	48,505
Unallocated corporate liabilities			4,716
Consolidated total liabilities			53,221

6. Loss from operations

The Group's loss for the period has been arrived at after charging:

	Six months ended 30 September	
	2023	2022
	HK\$'000	HK\$'000
	(Unaudited)	(Unaudited)
Depreciation of property, plant and equipment	4,368	2,761
Depreciation of right-of-use assets	1,490	1,614
Expense relating to short-term leases	224	10
Cost of inventories recognised as expenses	66,704	63,408
Staff costs (including directors' remuneration)	14,477	16,810
	<u>14,477</u>	<u>16,810</u>

7. Finance costs

	Six months ended 30 September	
	2023	2022
	HK\$'000	HK\$'000
	(Unaudited)	(Unaudited)
Interest on:		
– Lease liabilities	513	589
– Bank loans	380	349
	<u>893</u>	<u>938</u>

8. Taxation

	Six months ended 30 September	
	2023	2022
	HK\$'000	HK\$'000
	(Unaudited)	(Unaudited)
Current tax:		
– PRC Enterprise Income Tax	146	396
	<u>146</u>	<u>396</u>

The Group was not subject to any taxation under the jurisdiction of the Cayman Islands and British Virgin Islands during the Period (2022: Nil).

No provision for Hong Kong profits tax had been provided as the Group had no estimated assessable profit arising in Hong Kong during the Period (2022: Nil).

The Ministry of Finance (“MOF”) and State Administration of Taxation (“SAT”) on 17 January 2019 jointly issued Cai Shui 2019 No.13. This clarified that from 1 January 2019 to 31 December 2021, eligible small enterprises whose RMB1,000,000 of annual taxable income is eligible for a 75% reduction on a rate of 20% (i.e., effective rate is 5%) and the income between RMB1,000,000 and RMB3,000,000 is eligible for 50% reduction on a rate of 20% (i.e. effective rate is 10%). On 14 March 2022, MOF and SAT further jointly issued Cai Shui 2022 No. 13, which clarified that from 1 January 2022 to 31 December 2022, eligible small enterprises whose income between RMB1,000,000 and RMB3,000,000 is eligible for 75% reduction on a rate of 20% (i.e. effective rate is 5%). Thus, the Group’s subsidiaries in the PRC were subject to Enterprise Income Tax at the rate of 5% based on the estimated assessable profit during the Period (2022: 5%).

9. Loss per share

The calculation of basic loss per share for the Period was based on the loss attributable to owners of the Company of approximately HK\$3,050,000 (2022: approximately HK\$2,506,000) and on the ordinary share of 560,222,136 shares (2022: ordinary shares of 560,222,136).

There were no diluted potential shares in existence during the Period (2022: Nil).

10. Property, plant and equipment

During the Period, the Group purchased property, plant and equipment with a total cost of approximately HK\$291,000 (2022: approximately HK\$555,000) and disposed property, plant and equipment with carrying amount of approximately HK\$24,000 (2022: approximately HK\$113,000).

11. Trade and other receivables

Payment terms with customers from the pharmaceutical wholesale and distribution business and hemodialysis treatment and consultancy service business are mainly on credit. Invoices are normally payable from 30 to 90 days of issuance. The following is an aged analysis of trade receivables based on invoice date at the end of the reporting period:

	30 September 2023 HK\$'000 (Unaudited)	31 March 2023 HK\$'000 (Audited)
0 to 90 days	33,602	34,050
91 to 180 days	6,949	8,186
181 to 365 days	2,371	2,740
Over 365 days	6,534	7,478
	49,456	52,454

12. Share capital

	At 30 September 2023 HK\$'000	At 31 March 2023 HK\$'000
<i>Authorised:</i>		
1,000,000,000 ordinary shares of HK\$0.05 per share	<u>50,000</u>	<u>50,000</u>
<i>Issued and fully paid:</i>		
560,222,136 ordinary shares of HK\$0.05 per share	<u>28,011</u>	<u>28,011</u>

13. Trade and other payables

	At 30 September 2023 HK\$'000 (Unaudited)	At 31 March 2023 HK\$'000 (Audited)
Trade payables ^{Note}	30,844	16,965
Accruals and other payables	4,627	4,857
Deposits received	<u>1,954</u>	<u>2,075</u>
	<u>37,425</u>	<u>23,897</u>

Note:

The credit period on purchases of certain goods is ranged from 30 to 90 days. The following is an aged analysis of trade payables based on invoice date at the end of the reporting period:

	At 30 September 2023 HK\$'000 (Unaudited)	At 31 March 2023 HK\$'000 (Audited)
0 to 90 days	21,481	7,542
91 to 180 days	4,242	1,575
181 to 365 days	787	2,722
Over 365 days	<u>4,334</u>	<u>5,126</u>
	<u>30,844</u>	<u>16,965</u>

14. Amount due to a director

Amount due to a director is unsecured, interest free and repayable on demand.

15. Borrowings

	At 30 September 2023 HK\$'000 (Unaudited)	At 31 March 2023 HK\$'000 (Audited)
Bank borrowings – unsecured ^{Note (a)}	3,863	6,856
Other loans – secured ^{Note (b)}	475	594
	<u>4,338</u>	<u>7,450</u>
Carrying amount repayable: Within one year or on demand	<u>4,338</u>	<u>7,450</u>

Notes:

- (a) At 30 September 2023, the unsecured bank loans of the Group are denominated in RMB. The effective interest rate of the unsecured bank loans as at 30 September 2023 are ranged from 7.10% to 14.40% per annum.
- (b) Certain of our PRC subsidiaries have entered into borrowing agreements with third-party financing companies during the period ended 30 September 2023. Pursuant to the loan agreements, loans are secured by vehicles with carrying amounts of RMB655,000 (equivalent to approximately HK\$703,000), guaranteed by certain of our other PRC subsidiaries and with floating interest rates in the range of People's Bank of China's loan prime rate plus 7.10% to 9.23% per annum.

16. Dividend

The Board does not recommend the payment of an interim dividend for the Period (2022: Nil).

17. Related party transactions

During the reporting period, other than those transactions and balances detailed elsewhere in the Interim Financial Statements, the Group had the following significant transactions with related parties which, in the opinion of the Directors, were carried out on normal commercial terms and in the ordinary course of the Group's business:

a) *Key management personnel remuneration*

Remuneration for key management personnel, including amount paid to the Directors and other members of key management during the period were as follows:

	Six months ended 30 September	
	2023	2022
	HK\$'000	HK\$'000
	(Unaudited)	(Unaudited)
Salaries, allowances and benefits in kind	1,550	1,460
Provident fund contributions	36	36
	<u>1,586</u>	<u>1,496</u>

b) *Transaction with related parties*

During the reporting period, the Group had the following transactions with related parties:

	Six months ended 30 September	
	2023	2022
	HK\$'000	HK\$'000
	(Unaudited)	(Unaudited)
Expense relating to short-term lease with Mr. Wang Jia Jun	<u>90</u>	<u>90</u>

The Group had entered into a number of transactions with connected parties which, upon the listing of shares on the Stock Exchange, became connected persons of the Company under the Listing Rules. These transactions are continuing transactions exempt from the independent shareholder's approval requirements under the Listing Rules.

18. Approval of the condensed consolidated interim financial statements

The condensed consolidated interim financial statements were approved and authorised for issue by the Board on 27 November 2023.

MANAGEMENT DISCUSSION AND ANALYSIS

BUSINESS REVIEW

The Company is an investment holdings company and the Group is principally engaged in the pharmaceutical wholesale and distribution business and the hemodialysis treatment and consultancy service business in the PRC.

Pharmaceutical wholesale and distribution business (the “Wholesale Business”)

The Group has a broad customer base through our distribution network in Fujian Province in the PRC. The Group distributes pharmaceutical products to our customers located principally in the Fujian Province. Our customers can be categorized into three types namely hospitals and healthcare institutions and end customers such as companies operating pharmaceutical retail chain stores, independent pharmacies, and outpatient departments of community hospitals, healthcare service stations and clinics.

The revenue generated from this segment was approximately HK\$25.139 million (2022: approximately HK\$27.560 million), representing a decrease of approximately 8.78%. Profit approximately HK\$0.126 million (2022: approximately HK\$0.280 million) from this segment was recorded.

Hemodialysis treatment and consultancy service business (the “Hemodialysis Business”)

In respect of the Hemodialysis Business, the Group currently operates several self-operated hemodialysis treatment centers spread across the Guangdong Provinces, PRC. The Group has recorded an increase of revenue from the Hemodialysis Business during the Period. The increase was mainly attributable to the increased number of patients treated in our treatment centres. During the Period, the revenue generated from this segment was approximately HK\$68.234 million (2022: approximately HK\$62.586 million), representing an increase of approximately 9.02%. Profit approximately HK\$2.473 million (2022: approximately HK\$2.089 million) from this segment was recorded.

Outlook and Prospects

The Group will centralise its resources in developing the hemodialysis treatment and consultancy service business. The Group will look to further develop its hemodialysis treatment and consultancy service business through organic growth and acquisitions.

Looking forward, the Group will focus on developing such segment through establishment of new self-operated hemodialysis treatment centres and provide hemodialysis consultancy service to hospitals in the PRC so as to expand its operating scale and further penetrate in the market.

The Group believes that the demand for hemodialysis services in the PRC market is still far from being met and has great potential for development. Based on the Group's experience and strength in the medical field, the further exploration and expansion from our existing businesses to the continuously rising hemodialysis sector will become the driving force for building our further influence in the market and create better return to the shareholders.

The Group will continue to pay attention to different investment opportunities, identify appropriate businesses and projects for shareholders, and increase shareholders returns.

Interim Dividend

The Board has resolved not declare any interim dividend for the Period (2022: Nil).

FINANCIAL REVIEW

Revenue

For the Period, the revenue of the Group was approximately HK\$93.373 million (2022: approximately HK\$90.146 million), representing an increase of approximately HK\$3.227 million or approximately 3.58% when compared with the same period in 2022. The increase was driven by the increase in revenue from the Hemodialysis Business.

For the Period, the Group's revenue from the Wholesale Business was approximately HK\$25.139 million (2022: approximately HK\$27.560 million), representing a decrease of approximately HK\$2.421 million or approximately 8.78% when compared with the same period in 2022. The decrease was due to the decline in demand of certain medical products and supplies from hospitals and clinics due to the intense competition with other local medical distributors.

For the Period, the Group's revenue from the Hemodialysis Business was approximately HK\$68.234 million (2022: approximately HK\$62.586 million), representing an increase of approximately HK\$5.648 million or approximately 9.02% when compared with the same period in 2022. The increase was mainly attributable to the increase in number of patients treated in our hemodialysis treatment centres.

Gross Profit Margin

For the Period and the same period in 2022, the Group's gross profit margins were approximately 28.56% and approximately 29.66% respectively. The increase of production costs due to a rise in prices of key raw materials, which led to a slight increase in cost of sales and thus the Group's overall profitability in pharmaceutical distribution and hemodialysis services have been negatively impacted for the Period.

Other Revenue and Income

For the Period, the Group's other revenue and income was approximately HK\$3.011 million (2022: approximately HK\$0.259 million), representing an increase of approximately HK\$2.752 million when compared with the same period in 2022. The increase mainly arose from the gains on disposal of one of the Group's self-operated hemodialysis treatment centres in Huidong, Guangdong Province, the PRC. The disposal was completed on 11 May 2023.

Selling and Distribution Expenses

For the Period, the Group's selling and distribution expenses were approximately HK\$19.791 million (2022: approximately HK\$17.999 million), representing an increase of approximately HK\$1.792 million or approximately 9.96% when compared with the same period in 2022. The increase was mainly due to the increase of marketing expenses and logistics costs.

Administrative Expenses

For the Period, the Group's administrative expenses were approximately HK\$11.883 million (2022: approximately HK\$10.150 million), representing an increase of approximately HK\$1.733 million or approximately 17.07% when compared with the same period in 2022. The increase was mainly due to the increase of general office expenses such as depreciation, travelling and entertainment, and share option expenses for the Period.

Finance Costs

For the Period, the Group's finance costs were approximately HK\$0.893 million (2022: approximately HK\$0.938 million), representing a decrease of approximately 0.045 million when compared with the same period in 2022. It was due to the decrease of lease liabilities interest during the Period.

Taxation

During the Period, the Group's taxation expense was approximately HK\$0.146 million (2022: approximately HK\$0.396 million), which is the provision of income tax expense for the Hemodialysis Business.

Loss for the Period attributable to owners of the Company

As a result of the foregoing, the Group has recorded loss attributable to the owners of the Company was approximately HK\$3.050 million for the Period (2022: approximately HK\$2.506 million).

Total Comprehensive Expense

For the Period, the Group's total comprehensive expense attributable to the owners of the Company was approximately HK\$7.419 million (2022: approximately HK\$13.423 million) which was mainly due to the depreciation in exchange rate of RMB against HK\$ during the Period.

Capital Expenditure

The Group's capital expenditure requirements mainly related to additions of property, plant and equipments for the operation of hemodialysis treatment centres. The Group spent approximately HK\$0.291 million (2022: approximately HK\$0.555 million) on property, plant and equipment during the Period.

Liquidity and Financial Resources

The Group had total cash and cash equivalents of approximately HK\$15.765 million as at 30 September 2023 (31 March 2023: approximately HK\$9.876 million). The increase in cash balance was mainly arised from the cash proceeds in the amount of approximately HK\$3.990 million received from the disposal of one of the Group's self-operated hemodialysis treatment centres in Huidong, Guangdong Province, the PRC.

The Group recorded total current assets of approximately HK\$84.525 million as at 30 September 2023 (31 March 2023: approximately HK\$76.869 million) and total current liabilities of approximately HK\$49.143 million as at 30 September 2023 (31 March 2023: approximately HK\$38.074 million). The current ratio of the Group, calculated by dividing the current assets by the current liabilities, was approximately 1.72 as at 30 September 2023 (31 March 2023: approximately 2.02).

Contingent Liabilities

As at 30 September 2023, no member of the Group was engaged in any litigation or arbitration of material importance and no litigation or claim of material importance was known to the Directors to be pending or threatened against any member of the Group (31 March 2023: Nil).

Market risks

PRC government policy

The Group is very concerned about external regulatory compliance and environmental changes, and a management team is responsible for timely collection, interpretation and promotion of external regulatory requirements. The Group's management, together with the business line, will also discuss changes in the external environment, assess the impact of regulatory requirements on the existing business, and develop targeted countermeasures. The Group's compliance team will provide professional advice on the latest regulatory requirements and conduct compliance reviews on the compliance of existing regulations.

Foreign exchange and goodwill impairment risks

Since almost all transactions of the Group are denominated in Renminbi and Hong Kong dollars, most of the bank deposits are being kept in Renminbi and Hong Kong dollars to minimise exposure to foreign exchange risk, the Directors consider that the Group's risk exposure to currency fluctuations to be manageable. Therefore, the Group had not implemented any formal hedging or other alternative policies to deal with such exposure during the Period.

Impairment test for goodwill is based on the forecast of future cash flow and contains the management's relevant assumptions and professional judgements. Goodwill is exposed to certain risks of impairment.

Liquidity risk

In the management of the liquidity risk, the Group monitors and maintains the level of cash and cash equivalents deemed adequate by the management to finance the Group's operations and mitigate the effects of fluctuations in cash flow. The management manages liquidity risk by monitoring the utilisation of borrowings, adequacy of reserves and banking facilities by continuously monitoring forecast and actual cash flows.

Financing and Treasury Policies

The Group continues to adopt prudent financing and treasury policies. All the Group's financing and treasury activities are centrally managed and controlled. Implementation of the Group's related policies is made under collective but extensive considerations on liquidity risk, financing cost and exchange rate risk.

Material Acquisitions and Disposals

During the Period, the Group did not have any material acquisitions and disposals of subsidiaries, associates or joint ventures.

However, on 31 March 2023, one of the Group's self-operated hemodialysis treatment centres in Huidong, Guangdong Province, the PRC, namely Huidong Centre was disposed at RMB3.5 million (equivalent to approximately HK\$3.990 million). As of 11 May 2023, the disposal was completed. Please refer to the Company's announcement dated 31 March 2023 for further details.

Capital Commitments

As at 30 September 2023, the Group had no material capital commitment.

Employee Information

As at 30 September 2023, the Group had 198 (31 March 2023: 202) full time employees. During the six months ended 30 September 2023, the staff costs, including Directors' remuneration, totalled approximately HK\$14.477 million (2022: approximately HK\$16.810 million). Share options and bonuses are also available to the Group's employees at the discretion of the Board and depending upon the financial performance of the Group.

OTHER INFORMATION

Directors' And Chief Executive's Interests In Shares, Underlying Shares And Debentures Of The Company And Its Associated Corporations

Disclosure of Interests

(a) Directors' interest and short position in the securities of the Company

As at 30 September 2023, the interests and short positions of the directors and chief executive of the Company in the shares of the Company (“Shares”), underlying Shares and debentures of the Company or any of its associated corporation (within the meaning of Part XV of the Securities and Futures Ordinance (“SFO”)) which will have to be notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests and short positions which are taken or deemed to have under such provisions of the SFO) or which will be required, pursuant to Section 352 of the SFO, to be recorded in the register referred to therein or which will be required to be notified to the Company and the Stock Exchange pursuant to the Model Code for Securities Transactions by Directors of Listed Issuers (the “Model Code”) contained in the Appendix 10 to the Listing Rules, were as follows:

Long position in Shares and underlying Shares of the Company

Name of Director	Nature of interests	Total interests in ordinary Shares	Total interests in underlying Shares	Aggregate interests	Approximate percentage of issued Shares
Mr. Wang Jia Jun (“Mr. Wang”) (Note 1)	Interest of spouse	156,862,198	2,500,000	168,755,611	30.12%
	Beneficial owner	–	9,393,413		
Mr. Wong Hon Kit (“Mr. Wong”) (Note 2)	Beneficial owner	–	340,419	340,419	0.06%
Dr. Liu Yongping (“Dr. Liu”) (Note 2)	Beneficial owner	–	340,419	340,419	0.06%
Mr. Ho Man (“Mr. Ho”) (Note 2)	Beneficial owner	–	340,419	340,419	0.06%

Notes:

1. Mr. Wang is the beneficial owner of 9,393,413 share options. Mr. Wang (being the spouse of Ms. Yung Ka Lai (“Ms. Yung”)) is deemed to be interested in 2,500,000 share options owned by Ms. Yung. Power King Investment Development Limited (“Power King”), a company wholly-owned by Ms. Yung, owns a total of 156,862,198 Shares. Each of Ms. Yung and Mr. Wang is, therefore, deemed to be interested in the 9,393,413 and 2,500,000 share options respectively and the 156,862,198 Shares held by Power King, under the SFO. Ms. Yung resigned as the Director with effect from 15 October 2021.

2. Mr. Wong, Dr. Liu and Mr. Ho are interested in share options which can be exercised to subscribe 340,419 Shares, 340,419 Shares and 340,419 Shares, respectively.

Save as disclosed above, as at 30 September 2023, the Directors of the Company were not aware of any other person (other than the Directors and chief executive of the Company) who had interests or short positions in the shares or underlying shares of the Company as recorded in the register required to be kept by the Company under Section 336 of the SFO.

(b) Substantial shareholders' interests and short positions in shares and underlying shares

As at 30 September 2023, other than the interests of a director or chief executive of the Company as disclosed under the heading "Directors' and chief executive's interest in shares, underlying shares and debentures of the Company and its associated corporations" above, the following persons (not being a director or the chief executive officer of the Company) have an interest or a short position in Shares or underlying Shares which would be required to be disclosed to the Company and the Stock Exchange under the provisions of Divisions 2 and 3 of Part XV of the SFO, or which were recorded in the register to be kept by the Company under Section 336 of the SFO:

Name	Nature of interests	Number of Shares (Long position)	Approximate percentage of total issued Shares
Power King (Note 1)	Beneficial owner	156,862,198	28.00%
Expert Wealth Investments Limited	Interest in controlled corporation (Note 2)	156,862,198	28.00%
Grand Harbour Finance Limited	Interest in controlled corporation (Note 2)	156,862,198	28.00%
Ng Kwok Fai	Beneficial owner of controlled corporation (Note 2)	156,862,198	28.00%

Note 1: Power King is interested in 156,862,198 Shares. The issued share capital of Power King is wholly-owned by Ms. Yung. Mr. Wang is deemed to be interested in the Shares in which Power King is interested in under the SFO.

Note 2: Based on the notifications filed to the Company, 156,862,198 Shares owned by Power King were pledged to Grand Harbour Finance Limited. Grand Harbour Finance Limited is wholly owned by Expert Wealth Investments Limited and Mr. Ng Kwok Fai is the controlling shareholder. As all these companies were deemed or taken to be interested in all the security in 156,862,198 Shares by virtue of the SFO, and therefore Expert Wealth Investments Limited and Mr. Ng Kwok Fai were deemed to have approximately 28.00% of interest in the Company as at 30 September 2023. To the best of the knowledge, information and belief of the Directors, after having made all reasonable enquires, Grand Harbour Finance Limited and its ultimate owner(s) are independent from and not connected with the Company and its connected persons (as defined in the Listing Rule).

Save as disclosed above, none of the Directors nor their spouses or children under 18 years of age were granted or had exercised any rights to subscribe for any securities of the Company or any of its associated corporations.

SHARE OPTIONS GRANTED TO DIRECTORS AND EMPLOYEES

Particulars of the Company's share option scheme are set out in the Share Option Scheme section.

During the period ended 30 September 2023, there would have 86,473,892 share options granted under the 2013 Share Option Scheme which remain outstanding or unexercised, details of which are as follows:

Type of participants	Number of share options					As at 30 September 2023	Date of grant	Exercise price (HK\$)	Exercise period
	As at 1 April 2023	Granted during the Period (Note 3)	Exercised during the Period	Lapsed during the Period	Cancelled during the Period				
Director									
Mr. Wang	3,793,413		-	-	-	1,293,413	26 October 2018	0.668	(Note 1)
		5,600,000	-	-	-	2,500,000	24 April 2020	0.190	(Note 2)
			-	-	-	5,600,000	5 September 2023	0.094	(Note 3)
Mr. Wong	140,419		-	-	-	40,419	26 October 2018	0.668	(Note 1)
		200,000	-	-	-	100,000	24 April 2020	0.190	(Note 2)
			-	-	-	200,000	5 September 2023	0.094	(Note 3)
Dr. Liu	140,419		-	-	-	40,419	26 October 2018	0.668	(Note 1)
		200,000	-	-	-	100,000	24 April 2020	0.190	(Note 2)
			-	-	-	200,000	5 September 2023	0.094	(Note 3)
Mr. Ho	140,419		-	-	-	40,419	26 October 2018	0.668	(Note 1)
		200,000	-	-	-	100,000	24 April 2020	0.190	(Note 2)
			-	-	-	200,000	5 September 2023	0.094	(Note 3)
Sub-total	4,214,670	6,200,000	-	-	-	10,414,670			
Employees									
	26,259,222		-	-	-	11,689,222	26 October 2018	0.668	(Note 1)
		49,800,000	-	-	-	14,570,000	24 April 2020	0.190	(Note 2)
			-	-	-	49,800,000	5 September 2023	0.094	(Note 3)
Sub-total	26,259,222	49,800,000	-	-	-	76,059,222			
Total	30,473,892	56,000,000	-	-	-	86,473,892			

Notes:

- The share options granted on 26 October 2018 are exercisable from 26 October 2018 to 26 October 2028.
- The share options granted on 24 April 2020 are exercisable from 24 April 2020 to 24 April 2030.
- The share options granted on 5 September 2023 are exercisable from 5 September 2023 to 5 September 2033. The share options granted will be vested over a period of twelve months from the date of grant.

The fair value of the share options granted on 5 September 2023 determined using the Binomial model was approximately HK\$2,210,000. The significant inputs into the model were share price of HK\$0.092 at the grant date, exercise price shown above, expected volatility of 59.904%, annual risk free interest rate of 3.89% and dividend payout ratio of Nil. The volatility measured at the standard deviation of expected share price returns is based on statistical analysis of daily share prices from 11 October 2013 to 5 September 2023.

- Among the 3,900,000 share options granted to the employees of the Company's subsidiaries in the PRC, these share options are exercisable in the following manner: (i) up to 30% of the share options granted to each grantee shall be exercisable on or after 24 April 2020 to 23 April 2021; (ii) up to further 30% of the share options granted to each grantee shall be exercisable on or after 24 April 2021 to 23 April 2022; and (iii) all the remaining 40% of the share options granted to each grantee shall be exercisable on or after 24 April 2022 to 23 April 2023, and in each case, not later than 24 April 2030.

DIRECTORS' RIGHTS TO ACQUIRE SECURITIES

Apart from as disclosed under the heading “Directors’ and chief executive’s interests in shares, underlying shares and debentures” above, at no time since incorporation of the Company were rights to acquire benefits by means of the acquisition of shares in or debentures of the Company or of any other body corporate granted to any Directors or their respective spouse or children under 18 years of age, or were any such rights exercised by them; or was the Company, its holding company or any of its subsidiaries a party to any arrangement to enable the Directors, their respective spouse or children under 18 years of age to acquire such rights in any other body corporate.

SHARE OPTION SCHEME

According to the share option scheme adopted pursuant to the written resolutions of the shareholder dated 24 September 2013 (the “**2013 Share Option Scheme**”), the 2013 Share Option Scheme should expire on 24 September 2023. The share options granted thereunder prior to the expiry date will continue to be valid and exercisable in accordance with the terms of the 2013 Share Option Scheme. At the annual general meeting of the Company held on 15 September 2023, the shareholders of the Company approved the termination of the 2013 Share Option Scheme and adoption of a new share option scheme (the “**2023 Share Option Scheme**”) under which the Directors may grant share options to eligible persons to subscribe for the Shares, subject to the terms and conditions as stipulated therein. Unless otherwise cancelled or amended, the 2023 Share Option Scheme will remain valid for a period of 10 years from the date of its adoption.

The 2023 Share Option Scheme will provide the eligible participants an opportunity to have a personal stake in the Company with the view to achieving the following objectives: (i) motivate the eligible participants to optimise their performance efficiency for the benefit of the Group; and (ii) attract and retain or otherwise maintain an ongoing business relationship with the eligible participants whose contributions are or will be beneficial to the long-term growth of the Group. The eligible participants include the director(s) and employee(s) (whether full-time or part-time) of the Company or any member of the Group as determined or approved by the Board and the Remuneration Committee from time to time and in compliance with the Listing Rules. The eligible participants do not include service providers and service provider sublimit is not applicable. The Company is entitled to grant up to 56,022,213 share options under the 2023 Share Option Scheme during the Period. Details of the 2023 Share Option Scheme are set out in the circular of the Company dated 26 July 2023. No share options had been granted under the 2023 Share Option Scheme.

PURCHASE, SALE OR REDEMPTION OF THE COMPANY'S LISTED SHARES

During the period ended 30 September 2023, there was no purchases, sales or redemptions of the Company's listed securities by the Company or any of its subsidiaries.

PRE-EMPTIVE RIGHTS

There are no provisions for pre-emptive rights under the Company's Articles of Association or the laws of Cayman Islands, which would oblige the Company to offer new Shares on a pro-rata basis to existing shareholders.

COMPLIANCE WITH THE MODEL CODE FOR SECURITIES TRANSACTIONS BY DIRECTORS

The Company has adopted a code of conduct regarding securities transactions by the Directors on terms no less exacting than the required standard set out in the Model Code. The Company has made specific enquiry with all Directors and all the Directors have confirmed their compliance with the required standards set out in the Model Code throughout the period ended 30 September 2023.

CORPORATE GOVERNANCE

The Company strived to maintain a high standard of corporate governance and complied with the Corporate Governance Code set out in Appendix 14 to the Listing Rules. To the knowledge of the Board, the Company had fully complied with the code provisions in the Corporate Governance Code for the Period except code provision A.2.1 stipulates that the roles of chairman and chief executive officer should be separate and should not be performed by the same individual. After the former chairman resigned from the Company in 2014, there is no position of the chairman. The company did not have the chairman for the Period. The Board considered that the existing Board members were able to share the power and responsibilities of chairman among themselves for the Period.

Mr. Wang Jia Jun has been appointed as the Chief Executive Officer of the Company since 1 April 2020. The Company will, from time to time, review the effectiveness of the Group's corporate governance structure and consider whether any changes, including the establishment of the role of the chairman, are necessary.

REMUNERATION COMMITTEE

The Remuneration Committee of the Company (the “**Remuneration Committee**”) was established on 24 September 2013 in compliance with written terms of reference in compliance with Rule 3.25 of the Listing Rules. The Remuneration Committee consists of one executive Director, namely Mr. Wang Jia Jun, and three independent non-executive Directors, namely Mr. Wong Hon Kit, Dr. Liu Yongping and Mr. Ho Man. Mr. Wong Hon Kit is the chairman of the Remuneration Committee.

The role and function of the Remuneration Committee include, but are not limited to, the determination of the specific remuneration package of all executive Directors, including benefits in kind, pension rights and compensation payments, including any compensation payable for loss or termination of their office or appointment, and making recommendations to the Board of the remuneration of non-executive Directors. The Remuneration Committee considers factors such as salaries paid by comparable companies, time commitment and responsibilities of the Directors, employment conditions elsewhere in the Group and desirability of performance-based remuneration.

The grant of the share options is reviewed and approved by the Remuneration Committee, which is of the view that the grantees and number of share options granted are determined based on the work performance of the grantees and additional performance targets are not necessary. The Remuneration Committee considers that the grant of share options with no performance target aligned with the purpose of the 2013 Share Option Scheme to motivate the grantees and reinforce their commitment to long term services of the Group.

NOMINATION AND CORPORATE GOVERNANCE COMMITTEE

The Nomination and Corporate Governance Committee of the Company (the “**Nomination and Corporate Governance Committee**”) was established on 24 September 2013 in compliance with written terms of reference in compliance with paragraphs A.5.1 and D.3.1 of Appendix 14 to the Listing Rules. The Nomination and Corporate Governance Committee consists of one executive Director, namely Mr. Wang Jia Jun, and three independent non-executive Directors, namely Mr. Wong Hon Kit, Dr. Liu Yongping and Mr. Ho Man. Mr. Wang Jia Jun is the chairman of the Nomination and Corporate Governance Committee.

The primary duties of the Nomination and Corporate Governance Committee include, but are not limited to: (i) reviewing the structure, size and composition (including the skills, knowledge and experience) of the Board on a regular basis and making recommendations to the Board regarding any proposed changes; (ii) identifying individuals suitably qualified to become members of the Board and selecting or making recommendations to the Board on the selection of, individuals nominated for directorships; (iii) making recommendations to the Board on relevant matters relating to the appointment or re-appointment of Directors and succession planning for Directors in particular the chairman of the Board and the chief executive officer of the Company; and (iv) keeping the effectiveness of the corporate governance and system of internal controls of the Group.

AUDIT COMMITTEE

The Audit Committee of the Company (the “**Audit Committee**”) was established on 24 September 2013 in compliance with written terms of reference in compliance with Rules 3.21 of the Listing Rules. The Audit Committee consists of three independent non-executive Directors, namely Mr. Wong Hon Kit, Dr. Liu Yongping and Mr. Ho Man. Mr. Wong Hon Kit is the chairman of the Audit Committee.

The primary duties of the Audit Committee include, but are not limited to: (i) to review and monitor the external auditors’ independence and objectivity and the effectiveness of the audit process in accordance with applicable standard; (ii) monitoring integrity of financial statements of the Company and the Company’s annual report and accounts and the interim report; (iii) reviewing the Company’s financial controls, internal control and risk management systems; and (iv) reporting to the Board on the matters set out in the code provisions as stated in Appendix 14 to the Listing Rules.

The Group's unaudited condensed consolidated results for the Period were reviewed by the Audit Committee, which was of the opinion that the preparation of such results complied with the applicable accounting standards and requirements and that adequate disclosures were made.

SUFFICIENCY OF PUBLIC FLOAT

Based on the information available to the Company and within the knowledge of the Directors, the Company maintained adequate public float since the listing of the Shares on 11 October 2013.

PUBLICATION OF UNAUDITED INTERIM REPORT

The interim report is published on the websites of the Stock Exchange (www.hkexnews.hk) and the Company (www.wanjia-gp.com) respectively.

By order of the Board
Wanjia Group Holdings Limited
Wang Jia Jun
Chief Executive Officer and Executive Director

Hong Kong, 27 November 2023